MiNK Therapeutics Files Q1 2025 10-Q
Ticker: INKT · Form: 10-Q · Filed: May 15, 2025 · CIK: 1840229
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: AGEN
TL;DR
MiNK Therapeutics filed its Q1 2025 10-Q. Financials and operational updates inside.
AI Summary
MiNK Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its operations. Key financial items include retained earnings and general administrative expenses, with specific figures to be detailed within the full report.
Why It Matters
This filing provides investors with the latest financial health and operational status of MiNK Therapeutics, crucial for understanding its current performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotech company, MiNK Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (The period covered by this 10-Q filing.)
- 2025-03-31 — As of Date (The specific date for which financial information is reported.)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Filer of the 10-Q
- AgenTus Therapeutics, Inc. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250515 (date) — Filing date
- Agenus Inc. (company) — Related entity
FAQ
What were MiNK Therapeutics' total revenues for the quarter ended March 31, 2025?
The provided text does not contain specific revenue figures for the quarter ended March 31, 2025.
What is the net loss or income reported for the first quarter of 2025?
The filing summary does not include net loss or income details for the period ending March 31, 2025.
What are the details of MiNK Therapeutics' cash and cash equivalents as of March 31, 2025?
Specific figures for cash and cash equivalents are not present in the provided excerpt.
Were there any significant research and development expenses incurred during the first quarter of 2025?
The filing mentions 'us-gaap:ResearchAndDevelopmentExpenseMember' for the period 2024-01-01 to 2024-03-31, but specific Q1 2025 R&D expenses are not detailed in this summary.
What is the company's current cash runway based on the Q1 2025 filing?
Information regarding the company's cash runway is not available in the provided text.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding MiNK Therapeutics, Inc. (INKT).